<DOC>
	<DOCNO>NCT01818713</DOCNO>
	<brief_summary>Leptomeningeal metastasis ( LM ) develop tumor cell reach cerebrospinal fluid ( CSF ) infiltrate leptomeninges . The median survival patient breast cancer LM 4-6 month 25 % long-term survivor . Many potentially highly efficacious intravenous chemotherapy currently effective treat LM adequately cross blood-CSF barrier . Doxorubicin , anthracycline chemotherapeutic agent , well-established antineoplastic activity breast cancer . To optimally enhance delivery liposomal doxorubicin brain , to-BBB technology B.V. design glutathione ( GSH ) pegylated liposomal doxorubicin hydrochloride formulation ( 2B3-101 ) . Coating liposome PEG ensure prolong circulation time plasma , whilst conjugation GSH tip PEG molecule target liposomes towards active GSH transporter BBB enhance delivery doxorubicin brain . This clinical pharmacological study aim determine preliminary efficacy treatment 2B3-101 patient leptomeningeal metastasis breast cancer use LM response score .</brief_summary>
	<brief_title>Clinical Pharmacological Study With 2B3-101 Patients With Breast Cancer Leptomeningeal Metastases</brief_title>
	<detailed_description>Leptomeningeal metastasis ( LM ) develop tumor cell reach cerebrospinal fluid ( CSF ) infiltrate leptomeninges . Clinically symptomatic LM affect approximately 5 percent patient metastatic cancer . Among patient LM cause solid tumor , common tumor type breast cancer ( 12-35 % ) , lung cancer ( 10-26 % ) , melanoma ( 5-25 % ) gastrointestinal malignancy ( 4-14 % ) . One seven percent LM patient unknown primary tumor . The median survival untreated patient LM derive solid tumor 6-8 week . Chemotherapy radiotherapy symptomatic central nervous system ( CNS ) sit extends median survival 2-4 month . The median survival patient breast cancer LM even longer ( 4-6 month ) 25 % long-term survivor . Many potentially highly efficacious intravenous chemotherapy currently effective treat LM adequately cross blood-CSF barrier . The effectiveness intrathecal ( IT ) chemotherapy think limited due rapid cerebrospinal fluid ( CSF ) clearance drug and/or insufficient penetration large ( &gt; 1mm ) tumor deposit subarachnoid space . Besides , cytostatic drug administer intrathecally neurotoxicity . Doxorubicin , anthracycline chemotherapeutic agent , well-established antineoplastic activity breast cancer . It triple action mechanism , namely bind DNA strand intercalation , block enzyme topoisomerase II , necessary DNA replication formation free radical . The treatment breast cancer patient anthracycline-containing adjuvant chemotherapy reduces relative risk ( RR ) mortality breast cancer patient ± 38 % per year patient young 50 year ± 20 % patient 50 69 year . [ 6 ] To optimally enhance delivery liposomal doxorubicin brain , to-BBB technology B.V. design glutathione ( GSH ) pegylated liposomal doxorubicin hydrochloride formulation ( 2B3-101 ) . Coating liposome PEG ensure prolong circulation time plasma , whilst conjugation GSH tip PEG molecule target liposomes towards active GSH transporter BBB enhance delivery doxorubicin brain . In ongoing Phase I/IIa study ( M11TBB ) safety preliminary efficacy 2B3-101 determined patient brain metastasis solid tumour patient recurrent malignant glioma 7 hospital The Netherlands , Belgium , France USA . This feasibility study aim determine preliminary efficacy treatment 2B3-101 patient leptomeningeal metastasis breast cancer use LM response score ( see table 2 ) . To examine enhanced delivery 2B3-101 central nervous system ( brain CSF ) , measurement doxorubicin brain interstitial space CSF indicate . Technically , doxorubicin measurement brain interstitial space difficult , invasive probe ( microdialysis open probe ) position brain tissue . Measurement free doxorubicine CSF easy CSF obtain lumbar puncture patient LM treat 2B3-101 . Doxorubicine CSF level compare doxorubicine plasma level . Doxorubicine measure total doxorubicine ( free doxorubicine + liposomal doxorubicine ) free doxorubicin . To measure anti-tumor response 2B3-101 leptomeningeal metastasis plan explore enumeration circulate tumor cell ( CTC ) prior 2B3-101 therapy , use fluorescence-activated cell sort ( FACS ) flow cytometry method currently validate ongoing study N12CLM ( NKI/AvL ) . The CTC method determine single cell change epithelial cell adhesion molecule ( EpCAM ) positive tumor , like breast cancer .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Inclusion criterion : 1 . Age ≥ 18 year . 2 . Radiological cytological evidence clinically LM pathologically confirm breast cancer . 3 . Concomitant brain metastasis allow 4 . ECOG Performance Status ≤ 2 . 5 . Estimated life expectancy least 8 week . 6 . Stable/decreasing dosage steroid ( e.g.dexamethasone ) 7 day prior baseline MRI . 7 . Use nonenzyme induce antiepileptic drug allow . 8 . Toxicities incur result previous anticancer therapy ( radiation therapy , chemotherapy , surgery ) must resolve ≤ grade 2 ( define CTCAE version 4.0 ) . 9 . Written inform consent accord local guideline . 10 . Local radiation CNS symptomatic site four week prior start study allow . Exclusion criterion : 1 . Less 4 week last treatment chemotherapy , biological therapy , immunotherapy , endocrine therapy le 6 week nitrosoureas mitomycin C. 2 . Less 4 week last radiotherapy brain spinal cord/cauda equine . 3 . Patients receive maximum cumulative dose free ( i.e. , nonliposomal ) liposomal doxorubicin &gt; 360mg/m2 free epirubicin &gt; 600mg/m2 4 . Current recent ( less 4 week first 2B3101 treatment ) treatment another investigational drug . 5 . Any current anticancer therapy 6 . Inadequate bone marrow function , define : Absolute Neutrophil Count ( ANC ) : &lt; 1.5 x 109/L , platelet count &lt; 100 x 109/L haemoglobin &lt; 6 mmol/L . 7 . Inadequate liver function 8 . Inadequate renal function 9 . Pregnancy lactation 10 . For female subject childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) male subject surgically sterile female partner childbearing potential : absence effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal gel ) . 11 . Major surgical procedure ( include open biopsy , exclude central line IV Portacath ) within 4 week prior first study treatment , anticipation need major surgery course study treatment . 12 . Grade 3 4 motor , sensory , cranial neuropathy symptom ( define CTCAE version 4.0 ) cause previous chemotherapy . 13 . Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100mm Hg ) . 14 . Clinically significant ( i.e . active ) cardiovascular disease define : Stroke within 6 month prior treatment 2B3101 ( day 1 ) ; Transient Ischaemic Attack ( TIA ) within 6 month prior day 1 ; Myocardial infarction ( MI ) within ≤ 6 month prior day 1 ; Unstable angina pectoris ( AP ) ; New York Heart Association ( NYHA ) Grade II great Congestive Heart Failure ( CHF ) ; Cardiac arrhythmia , except stable atrium fibrillation ; 15 . LVEF MUGA ECHO &lt; 50 % . 16 . Known hypersensitivity study drug component excipients ( doxorubicin , PEG GSH ) . 17 . Evidence medical condition may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication . 18 . Contraindications lumbar puncture : blood clot disorder ( INR &gt; 1.5 , platelet &lt; 20x109 /l , aPTT &gt; 1.5 ULN ) . Lumbar puncture platelet transfusion result platelet &gt; 20x109 /l transfusion allow . therapeutic anticoagulant treatment interrupt 24 hour . Low dose prophylactic treatment low molecular weight heparin allow . cerebral spaceoccupying lesion risk cerebral herniation . spinal spaceoccupying lesion risk myelocompression conus/cauda compression . 19 . Active systemic CNS infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>2B3-101 , liposomal doxorubicin , leptomeningeal metastasis</keyword>
</DOC>